-
Jul 14, 2018 Apotex Focuses on High Growth Markets with Sale of European Generics Business
-
Jun 1, 2018 Apotex Builds Momentum in Canada's Biosimilar Market After World's First Approval
-
May 9, 2018 Apotex Announces Proposed Merger of AUS & NZ Operations
-
Jun 12, 2017 Apobiologix Applauds Supreme Court Decision in Sandoz Biosimilar Case
-
Jun 8, 2017 Canadian Scientists Honored for Role in Breakthrough Drug
-
Apr 28, 2017 University of Saskatchewan, Apotex renew partnership with $1.6M donation to the College of Pharmacy and Nutrition
-
Mar 8, 2017 Apotex Announces $184 Million Investment to Grow U.S. Manufacturing Presence; Expansion Plan Comprises Company's Largest Investment in the United States
-
Mar 31, 2016 Launch of Key Biosimilar Medicine To Help Save Healthcare Budgets
-
Mar 24, 2016 Apotex Launches First Generic Version of Merck's Nasonex®
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Jul 2, 2025
Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats
Apotex Inc., the Canadian-based global health company, today announced that Health Canada has approved Aflivu™ (aflibercept), a biosimilar to Eylea®, indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema secondary to central or branch retinal vein occlusion, treatment of diabetic macular edema, and treatment of myopic choroidal neovascularization.
-
May 25, 2025
Apotex launches nilotinib capsules, the first generic version of Tasigna®¹ in the United States, with 180 days of exclusivity
Nilotinib is a kinase inhibitor indicated to treat certain types of leukemia, including newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia ("Ph+ CML") in chronic phase in adults and children aged 1 year and older. It is also indicated for adults and pediatric patients with chronic or accelerated phase Ph+ CML with resistance or intolerance to prior therapy, demonstrating higher efficacy compared with other available treatments.
-
May 20, 2025
Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
Apotex's 2024 Sustainability Report underscores our commitment to advancing health and unlocking new possibilities through partnerships, while championing sustainability and responsible business practices. "As we continue to execute our Journey of Health growth strategy, our focus on sustainability ensures that we are meeting the needs of patients, physicians, and pharmacists, and contributing positively to the environment and society. This report reflects our dedication to these values, and to transparency, accountability, and long-term value creation," said Allan Oberman, President & CEO, Apotex.